Ivabradine in stable coronary artery disease without clinical heart failure.

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F14%3A33152278" target="_blank" >RIV/61989592:15110/14:33152278 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00843989:_____/14:E0106093

Výsledek na webu

<a href="http://www.nejm.org/doi/full/10.1056/NEJMoa1406430#t=articleTop" target="_blank" >http://www.nejm.org/doi/full/10.1056/NEJMoa1406430#t=articleTop</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1056/NEJMoa1406430" target="_blank" >10.1056/NEJMoa1406430</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Ivabradine in stable coronary artery disease without clinical heart failure.

Popis výsledku v původním jazyce

An elevated heart rate is an established marker of cardiovascular risk. Previous analyses have suggested that ivabradine, a heart-rate-reducing agent, may improve outcomes in patients with stable coronary artery disease, left ventricular dysfunction, anda heart rate of 70 beats per minute or more. We conducted a randomized, double-blind, placebo-controlled trial of ivabradine, added to standard background therapy, in 19,102 patients who had both stable coronary artery disease without clinical heart failure and a heart rate of 70 beats per minute or more We randomly assigned patients to placebo or ivabradine, at a dose of up to 10 mg twice daily, with the dose adjusted to achieve a target heart rate of 55 to 60 beats per minute. The primary end point was a composite of death from cardiovascular causes or nonfatal myocardial infarction.At 3 months, the mean (+-SD) heart rate of the patients was 60.7+-9.0 beats per minute in the ivabradine group versus 70.6+-10.1 beats per minute in the

Název v anglickém jazyce

Ivabradine in stable coronary artery disease without clinical heart failure.

Popis výsledku anglicky

An elevated heart rate is an established marker of cardiovascular risk. Previous analyses have suggested that ivabradine, a heart-rate-reducing agent, may improve outcomes in patients with stable coronary artery disease, left ventricular dysfunction, anda heart rate of 70 beats per minute or more. We conducted a randomized, double-blind, placebo-controlled trial of ivabradine, added to standard background therapy, in 19,102 patients who had both stable coronary artery disease without clinical heart failure and a heart rate of 70 beats per minute or more We randomly assigned patients to placebo or ivabradine, at a dose of up to 10 mg twice daily, with the dose adjusted to achieve a target heart rate of 55 to 60 beats per minute. The primary end point was a composite of death from cardiovascular causes or nonfatal myocardial infarction.At 3 months, the mean (+-SD) heart rate of the patients was 60.7+-9.0 beats per minute in the ivabradine group versus 70.6+-10.1 beats per minute in the

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FA - Kardiovaskulární nemoci včetně kardiochirurgie

OECD FORD obor

—

Projekt

—

Návaznosti

N - Vyzkumna aktivita podporovana z neverejnych zdroju

Rok uplatnění

2014

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

New England Journal of Medicine

ISSN

0028-4793

e-ISSN

—

Svazek periodika

371

Číslo periodika v rámci svazku

12

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

9

Strana od-do

1091-1099

Kód UT WoS článku

000341687300004

EID výsledku v databázi Scopus

—